Sorafenib for advanced hepatocellular carcinoma: a systematic review.
- Author:
Zou LING-LIN
1
;
Ma LI
;
Tian JIN-HUI
;
Yang KE-HU
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; adverse effects; therapeutic use; Benzenesulfonates; adverse effects; therapeutic use; Carcinoma, Hepatocellular; drug therapy; Humans; Liver Neoplasms; drug therapy; Niacinamide; analogs & derivatives; Phenylurea Compounds; Pyridines; adverse effects; therapeutic use
- From: Acta Academiae Medicinae Sinicae 2011;33(1):51-57
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo evaluate the effectiveness and toxicity of sorafenib for advanced hepatocellular carcinoma.
METHODSAccording to the Cochrane handbook for systematic review, two reviewers independently completed the whole process of literature search, study selection, data collection, and quality assessment. Seven electric databases(PubMed, Cochrane Library, Embase, Chinese Journal Full-text Database, Chinese Biomedical Literature Database, Chinese Scientific and Technical Journal Database, Chinese Medical Association Digital Periodicals Database) were searched and randomized controlled trials (RCT) of sorafenib in the treatment of advanced hepatocellular carcinoma were collected and analyzed.
RESULTSTwo RCT involving 828 patients were finally included. Compared with placebo, sorafenib significantly extended the overall survival and time to radiologic progression and improved the disease control rate. The main adverse effects were systemic, gastrointestinal, and dermatologic symptoms (grade 1 or 2 in severity), although the incidences were significantly higher in sorafenib groups than in control groups.
CONCLUSIONSorafenib is effective and safe for the treatment of advanced hepatocellular carcinoma.
